Corona virus
Upcoming SlideShare
Loading in...5
×
 

Corona virus

on

  • 3,439 views

Lecture By Dr.M

Lecture By Dr.M

Statistics

Views

Total Views
3,439
Views on SlideShare
3,439
Embed Views
0

Actions

Likes
7
Downloads
223
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Corona virus Corona virus Presentation Transcript

  • UPDATE, CASE DEFINITIONS, AND GUIDANCE MERS UPDATE
  • ?What is MERS CDC continues to work closely with the World Health Organization (WHO) and other partners to better understand the public health risk Middle East Respiratorypresented by -). MERSCoV-Coronavirus (MERSSyndrome CoV used to be called “novel coronavirus,” or “nCoV
  • What is the new human coronavirus? A novel coronavirus was identified in 2012 as the cause of respiratory illness in people. The new virus is a beta coronavirus. It is different from any other coronavirus previously found in people.
  • Is this virus the same as the SARS virus? the samenotisnovel coronavirusNo. The virus that caused severe acute respiratory syndrome (SARS) in 2003. However, like the SARS virus, the novel coronavirus is most similar to those found in bats. CDC is still learning about this new virus.
  • The first cluster of two cases The first cluster of two cases, both fatal, occurred near Amman, Jordan, in April 2012. Stored samples from these two cases tested positive retrospectively for the novel coronavirus. This cluster was temporally associated with cases of illness among workers in a hospital
  • A second cluster A second cluster occurred in October 2012, in Saudi Arabia. Of the four individuals in the household, three were laboratory-confirmed cases, two of them died
  • MERS Cases and Deaths, April 2012 - May 2013  Current as of June 11, 2013  Countries  Cases (Deaths)  France  2 (1)  Italy  3 (0)  Jordan  2 (2)  Qatar  2 (0)  Saudi Arabia  40 (26)  Tunisia  2 (0)  United Kingdom (UK)  3 (2)  United Arab Emirates (UAE)  1 (1)  Total  55 (32)
  • MERS Cases and Deaths, April 2012 - Present Countries Cases (Deaths) France 2 (1) Italy 3 (0) Jordan 2 (2) Qatar 2 (0) Saudi Arabia 53 (32) Tunisia 2 (0) United Kingdom (UK) 3 (2) United Arab Emirates (UAE) 1 (1) Total 68 (38) Current as of June 21, 2013, 9:00 AM EDT
  • -The original source of MERS ,CoV The original source of MERS-CoV, routes of transmission to humans, and mode of human- to-human transmission have not been determined. Genetic sequencing to date has determined the virus is most closely related to coronaviruses detected in bats. CDC is continuing to collaborate with WHO and affected countries to better characterize the epidemiology of MERS-CoV infection in humans.
  • What are the symptoms of novel coronavirus infection? Most people who got infected with the novel coronavirus developed severe acute respiratory illness with symptoms of fever, cough, and shortness of breath. Some people were reported as having a mild respiratory illness
  • Case Definitions  Patient Under Investigation (PUI)
  • Patient Under Investigation (PUI)  A person with an acute respiratory infection, which may include fever (≥ 38°C , 100.4°F) and cough; AND  suspicion of pulmonary parenchymal disease (e.g., pneumonia or acute respiratory distress syndrome based on clinical or radiological evidence of consolidation); AND  history of travel from the Arabian Peninsula or neighboring countries* within 10 days; AND
  • Probable Case  A person fitting the definition above of a “Patient Under Investigation” with clinical, radiological, or histopathological evidence of pulmonary parenchyma disease (e.g. pneumonia or ARDS) but no possibility of laboratory confirmation either because the patient or samples are not available or there is no testing available for other respiratory infections, AND  close contact with a laboratory confirmed case, AND  not already explained by any other infection or etiology, including all clinically indicated tests for community-acquired pneumonia according to local management guidelines.
  • Confirmed Case  A person with laboratory confirmation of infection with the novel coronavirus.
  • Does the virus spread from person to person? The virus has been shown to spread between people who are in close contact. Transmission from infected patients to healthcare personnel has also been observed. Clusters of cases in Saudi Arabia, Jordan, the UK and France are being investigated.
  • modes of transmission  There is clear evidence of human-to-human transmission, possibly involving different modes of transmission such as droplet and contact transmission. But further studies are required to better understand the risks. The efficiency of person-to-person transmission of novel coronavirus is not well characterized.
  • Can I still travel to countries in the Arabian Peninsula or neighboring countries Yes. WHO and CDC have not issued travel health warnings for any country related to novel coronavirus
  • What if I recently traveled to countries in the Arabian Peninsula or neighboring countries and got sick? If you develop a fever and symptoms of lower respiratory illness, such as cough or shortness of breath, within 10 days after traveling from countries in the Arabian , you)1(Peninsula or neighboring countries should see your healthcare provider and mention your recent travel
  • What are the treatments?  There are no specific treatments for illnesses caused by the novel coronavirus. Medical care is supportive and to help relieve symptoms.
  • Is there a lab test? Lab tests (polymerase chain reaction or PCR) for the novel coronavirus are available at CDC and other international labs. Otherwise, these tests are not routinely available
  • What should healthcare providers and health departments do For recommendations and guidance on the case definitions; infection control, including personal protective equipment guidance; case investigation; and specimen collection and shipment,
  • Infection control recommendations for healthcare settings Until the transmission characteristics of the novel coronavirus are better understood, patients under investigation and probable and confirmed cases should be managed according to CDC’s infection control recommendations for the coronavirus that caused SARS.
  • For Healthcare Providers Infection control recommendations for healthcare settings Standard, contact, and airborne precautions are recommended for management of hospitalized patients with known or suspected MERS-CoV infection. These recommendations are consistent with those recommended for the coronavirus that caused severe acute respiratory syndrome (SARS) in 2003. The recommendations are based on available information (as of June 10, 2013) and will be re- evaluated and updated as needed when new information becomes available